{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:49:32Z","timestamp":1785462572243,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ejpb.2024.114333","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T15:41:27Z","timestamp":1716046887000},"page":"114333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability"],"prefix":"10.1016","volume":"200","author":[{"given":"Xianzhi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-3106","authenticated-orcid":false,"given":"Wenqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2024.114333_b0005","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1021\/cg200492w","article-title":"Solubility advantage of amorphous drugs and pharmaceutical cocrystals","volume":"11","author":"Babu","year":"2011","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejpb.2024.114333_b0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jconrel.2017.07.047","article-title":"Mesoporous silica materials: from physico-chemical properties to enhanced dissolution of poorly water-soluble drugs","volume":"262","author":"Maleki","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2024.114333_b0015","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/10717544.2019.1704940","article-title":"Mechanisms of increased bioavailability through amorphous solid dispersions: a review","volume":"27","author":"Schittny","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114333_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js9601896","article-title":"Characteristics and significance of the amorphous state in pharmaceutical systems","volume":"86","author":"Hancock","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114333_b0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/pharmaceutics13030389","article-title":"Co-amorphous drug formulations in numbers: recent advances in co-amorphous drug formulations with focus on co-formability, molar ratio, preparation methods, physical stability, in vitro and in vivo performance, and new formulation strategies","volume":"13","author":"Liu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114333_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120448","article-title":"Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability","volume":"600","author":"Fael","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0035","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/pharmaceutics15020337","article-title":"Mechanism for stabilizing an amorphous drug using amino acids within co-amorphous blends","volume":"15","author":"Guinet","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114333_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105667","article-title":"Co-amorphous formation of piroxicam-citric acid to generate supersaturation and improve skin permeation","volume":"158","author":"Hirakawa","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114333_b0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1021\/acs.molpharmaceut.2c00057","article-title":"Design of a stable coamorphous system using lactose as an antiplasticizing agent for diphenhydramine hydrochloride with a low glass transition temperature","volume":"19","author":"Ueda","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0050","article-title":"Co-amorphous drug formulations in numbers: recent advances in co-amorphous drug formulations with focus on co-formability, molar ratio, preparation methods, physical stability, in vitro and in vivo performance, and new formulation strategies","author":"Liu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2024.114333_b0055","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ijpharm.2018.07.063","article-title":"Aspartame as a co-former in co-amorphous systems","volume":"549","author":"Wu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0060","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpharm.2012.05.016","article-title":"A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin","volume":"453","author":"L\u00f6bmann","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijpharm.2017.10.057","article-title":"On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems","volume":"535","author":"Wu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0070","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ejpb.2013.03.026","article-title":"Amino acids as co-amorphous stabilizers for poorly water-soluble drugs \u2013 Part 2: Molecular interactions","volume":"85","author":"L\u00f6bmann","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0075","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1080\/17425247.2020.1796631","article-title":"Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update","volume":"17","author":"Han","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2024.114333_b0080","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.9b00105","article-title":"Application of co-amorphous technology for improving the physicochemical properties of amorphous formulations","volume":"16","author":"Mizoguchi","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejps.2014.05.015","article-title":"Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: Improved dissolution behavior and physical stability without evidence of intermolecular interactions","volume":"62","author":"Dengale","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114333_b0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejps.2016.08.022","article-title":"Development of a screening method for co-amorphous formulations of drugs and amino acids","volume":"95","author":"Kasten","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114333_b0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejpb.2018.07.016","article-title":"Organic acids as co-formers for co-amorphous systems\u2013Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems","volume":"131","author":"Wu","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105582","article-title":"Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers","volume":"156","author":"Wu","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114333_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106526","article-title":"Dissolution changes in drug-amino acid\/biotin co-amorphous systems: decreased\/increased dissolution during storage without recrystallization","volume":"188","author":"Zou","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114333_b0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.trac.2017.04.005","article-title":"Determination of nucleosides and nucleotides in food samples by using liquid chromatography and capillary electrophoresis","volume":"92","author":"Dom\u00ednguez-\u00c1lvarez","year":"2017","journal-title":"TrAC Trends Anal. Chem."},{"key":"10.1016\/j.ejpb.2024.114333_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122707","article-title":"Tranilast-matrine co-amorphous system: Strong intermolecular interactions, improved solubility, and physiochemical stability","volume":"635","author":"Hu","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0120","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejps.2017.08.019","article-title":"Effect of surfactants and drug load on physico-mechanical and dissolution properties of nanocrystalline tadalafil-loaded oral films","volume":"109","author":"Vuddanda","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114333_b0125","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1248\/cpb.c18-00450","article-title":"Characterization and stability of amorphous tadalafil and four crystalline polymorphs","volume":"66","author":"Wei","year":"2018","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2024.114333_b0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/chem.19970030106","article-title":"Acid-base properties of adenosine 5\u2032-O-thiomonophosphate in aqueous solution","volume":"3","author":"Song","year":"1997","journal-title":"Chem. \u2013 Eur. J."},{"key":"10.1016\/j.ejpb.2024.114333_b0135","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1039\/DT9950000425","article-title":"Oxovanadium (IV) complexation by adenosine 5\u2032-di-and-tri-phosphate and nucleotide building blocks","author":"Alberico","year":"1995","journal-title":"J. Chem. Soc. Dalton Trans."},{"key":"10.1016\/j.ejpb.2024.114333_b0140","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/rcm.1229","article-title":"High-throughput screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry","author":"Wan","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ejpb.2024.114333_b0145","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ejps.2018.11.012","article-title":"Inclusion complexes of beta-cyclodextrin and polymorphs of mebendazole: physicochemical characterization","volume":"127","author":"Saidman","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2024.114333_b0150","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s11095-013-1232-z","article-title":"Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds","volume":"31","author":"Settimo","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114333_b0155","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1021\/mp0700108","article-title":"Celecoxib: nicotinamide dissociation: using excipients to capture the cocrystal's potential","volume":"4","author":"Remenar","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejpb.2018.11.016","article-title":"Dipeptides as co-formers in co-amorphous systems","volume":"134","author":"Wu","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0165","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1021\/acs.molpharmaceut.1c00144","article-title":"Amorphous salts solid dispersions of celecoxib: enhanced biopharmaceutical performance and physical stability","volume":"18","author":"Mukesh","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0170","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1021\/acs.jpcb.7b10105","article-title":"Glass-transition temperature of the \u03b2-relaxation as the major predictive parameter for recrystallization of neat amorphous drugs","volume":"122","author":"Kissi","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejpb.2024.114333_b0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpharm.2012.05.016","article-title":"A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin","volume":"453","author":"Korbinian","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0180","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0301-4622(03)00035-8","article-title":"A library of IR bands of nucleic acids in solution","volume":"104","author":"Banyay","year":"2003","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.ejpb.2024.114333_b0185","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jcis.2019.03.086","article-title":"Abiotic phosphorus recycling from adsorbed ribonucleotides on a ferrihydrite-type mineral: Probing solution and surface species","volume":"547","author":"Klein","year":"2019","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ejpb.2024.114333_b0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejpb.2016.09.011","article-title":"Physicochemical properties of direct compression tablets with spray dried and ball milled solid dispersions of tadalafil in PVP-VA","volume":"109","author":"Wlodarski","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0195","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijpharm.2019.05.010","article-title":"Evaluation of the solid state form of tadalafil in sub-micron thin films using nanomechanical infrared spectroscopy","volume":"565","author":"Samaeifar","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0200","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijpharm.2017.02.062","article-title":"Amorphous is not always better\u2014a dissolution study on solid state forms of carbamazepine","volume":"522","author":"Jensen","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-019-2700-x","article-title":"Gel formation induced slow dissolution of amorphous indomethacin","volume":"36","author":"Heng","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2024.114333_b0210","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/acs.molpharmaceut.9b00772","article-title":"Incorporation of complexation into a coamorphous system dramatically enhances dissolution and eliminates gelation of amorphous lurasidone hydrochloride","volume":"17","author":"Heng","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2024.114333_b0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejps.2018.12.016","article-title":"Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin","volume":"129","author":"Wei","year":"2019","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641124001590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T05:55:07Z","timestamp":1718603707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641124001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":43,"alternative-id":["S0939641124001590"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114333","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleotides as new co-formers in co-amorphous systems: Enhanced dissolution rate, water solubility and physical stability","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2024.114333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114333"}}